15.11.2024
MLP SE DE0006569908
Original-Research: MLP SE (von NuWays AG): Buy
Original-Research: MLP SE - from NuWays AG
15.11.2024 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
Classification of NuWays AG to MLP SE
Company Name: |
MLP SE |
ISIN: |
DE0006569908 |
|
Reason for the research: |
Update |
Recommendation: |
Buy |
from: |
15.11.2024 |
Target price: |
EUR 12.00 |
Target price on sight of: |
12 months |
Last rating change: |
|
Analyst: |
Henry Wendisch |
Q3 in line, guidance at top end or above achievable
Q3 sales increased by 19% yoy to € 245m (eNuW: € 242m; 9M: € 746m, +12% yoy), driven by a € 17m sales effect of performance fees (vs. Q3’23: € 0.1m) but also a solid underlying development (sales ex performance +11% yoy). The competence field Wealth drove sales by 36% yoy to € 140m (eNuW: € 128m; € 123m sales ex performance fees, up 19% yoy), whereas Life & Health sales also increased by 2% yoy to € 68m (eNuW: € 70m) followed by P&C sales of € 35m, up 2% yoy (eNuW: € 35m). Noteworthy, the RE business saw a two-faced development, where RE brokerage rose by 191% yoy and 17% qoq to € 10m (eNuW: € 8m) but RE development remained nonexistent at € 0m sales (eNuW: € 1m).
EBIT expanded sharply by 128% yoy to € 17.8m (eNuW: € 18.2m), benefiting from a € 11m performance fee EBIT contribution (eNuW; c. 65% incremental margin). On the other hand, underlying profitability (EBIT ex perf. fee effect) decreased by 13% yoy due to higher OPEX (+15% yoy).
Guidance confirmed: FY’24 guidance (EBIT: € 85-95m) confirmed: Based on a € 66m EBIT per 9M, the guidance implies a Q4 EBIT in the range of € 19-29m (eNuW: € 28m, not including significant performance fees). This also compares well to previous periods’ EBIT of € 23m (Q4'22, no perf. fees) and € 25m (Q4'23, no perf. fees), which were both burdened by goodwill impairments in the RE segment (€ 3m in Q4'22; € 4m in Q4'23). Consequently, we are positioned at the top end of the guidance (eNuW: € 95m). Moreover, should capital markets continue to perform well until Y/E'24e, performance fees could be in the cards and the guidance could be overachieved. For next year, MLP's midterm targets (EBIT € 100-110m; eNuW: € 102m) will become the FY'25e guidance and new mid-term targets are to be published with FY'24 results in March '25.
Dividend increase after 3 years likely: Based on MLP's targeted pay-out ratio of 50-70% (eNuW: 60%) and EPS estimate of € 0.64, the FY'24e dividend should amount to € 0.36 per share, implying a 20% yoy increase and a current yield of 6%. Mind you, that the dividend is tax free according to § 27 KStG.
All in all, MLP remains fully on track to achieve this and next year's targets this year and should continue to show improvements going forward thanks to its well diversified business model with a large share of recurring revenues. Therefore, we keep MLP in our NuWays' Alpha List and reiterate our BUY recommendation with unchanged PT of € 12.00, based on FCFY'24e.
You can download the research here: http://www.more-ir.de/d/31331.pdf
For additional information visit our website: www.nuways-ag.com/research
Contact for questions:
NuWays AG - Equity Research Web: www.nuways-ag.com Email: [email protected]LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
2030719 15.11.2024 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
608,74 |
642,14 |
689,56 |
745,52 |
907,30 |
913,79 |
941,13 |
EBITDA1,2 |
52,89 |
62,35 |
73,48 |
87,05 |
127,20 |
110,62 |
106,54 |
EBITDA-Marge3 |
8,69 |
9,71 |
10,66 |
11,68 |
14,02 |
12,11 |
|
EBIT1,4 |
37,60 |
46,39 |
47,10 |
59,36 |
96,81 |
75,61 |
70,72 |
EBIT-Marge5 |
6,18 |
7,22 |
6,83 |
7,96 |
10,67 |
8,27 |
7,51 |
Jahresüberschuss1 |
27,80 |
34,49 |
36,93 |
43,24 |
62,83 |
48,65 |
44,12 |
Netto-Marge6 |
4,57 |
5,37 |
5,36 |
5,80 |
6,93 |
5,32 |
4,69 |
Cashflow1,7 |
115,55 |
141,24 |
191,60 |
408,08 |
546,35 |
-292,45 |
116,67 |
Ergebnis je Aktie8 |
0,25 |
0,32 |
0,34 |
0,40 |
0,57 |
0,47 |
0,44 |
Dividende8 |
0,20 |
0,20 |
0,21 |
0,23 |
0,30 |
0,30 |
0,08 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: BDO
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
MLP |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
656990 |
5,830 |
Kaufen |
637,42 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
10,05 |
16,69 |
0,61 |
16,29 |
KBV |
KCV |
KUV |
EV/EBITDA |
1,24 |
5,46 |
0,68 |
5,98 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,30 |
0,30 |
5,15 |
25.06.2025 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
15.05.2025 |
14.08.2025 |
14.11.2024 |
27.03.2025 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-0,68% |
0,57% |
5,23% |
17,78% |
|
|